NVSEF - Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent

2025-09-04 10:29:48 ET

Monopar Overview - IPO, Management, Lead Drug Candidate

This is my first time covering Monopar Therapeutics Inc. ( MNPR ) for Seeking Alpha - first let's consider a business overview provided by the company in its Q2 2025 quarterly report / 10Q filing :

We are a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers along with Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. We leverage our scientific and clinical experience to help reduce the risk and accelerate the clinical development of our drug product candidates.

For further details see: